Composition comprising ganoderma lucidum mycelium and fermented product thereof for improving companion animal skin condition

Abstract

The present invention relates to a composition comprising a Ganoderma lucidum mycelium culture or a lactic acid bacteria fermented product of the culture for skin regeneration, alleviation of skin diseases such as atopy, allergy, etc., skin inflammation, enhancement of antibacterial or antifungal activity, and improvement of hair quality in companion animals.

Description

A composition for improving the skin of companion animals, comprising reishi mushroom mycelia and a fermented product thereof

[0001] The present invention relates to a composition for improving the skin or hair condition of a companion animal, comprising reishi mushroom mycelia or a marine lactic acid bacteria fermentation product of the mycelia culture.

[0002]

[0003] Most pets, including dogs and cats, have thinner dermis and are covered with long hair compared to humans. They lack sweat pores and have a slightly alkaline skin pH of 8-9. Furthermore, because pets' skin is covered with hair, it has limited contact with the outside air, making rashes and inflammation more likely to develop and difficult to detect. This increases the risk of skin diseases, which significantly impact the pet's health. Furthermore, pet skin harbors various bacteria, such as mites and demodex mites, which can damage not only the skin but also the hair, leading to hair-related problems like hair loss and matting.

[0004] Reishi (Ganoderma lucidum) is a mushroom native to various regions, including Korea, China, Japan, Greece, the United States, South America, and Australia. It is often called "Lucid Nurse Mushroom" or "Reishi Mushroom." It has been used in traditional Chinese and East Asian medicine for centuries and is incorporated into various health supplements and foods for health and therapeutic purposes. Reishi helps strengthen the immune system, reduces inflammation in the body, and is rich in antioxidants, protecting cells from free radicals and delaying aging. It can also be used to treat various inflammatory diseases.

[0005] Among the various effects of edible mushrooms including Reishi mushrooms, the function related to skin whitening is known through Korean Patent Publication No. 2010-0130109 and Korean Patent Publication No. 2005-0034833, and in particular, Korean Patent Publication No. 2013-0050751 relates to 'Novel compound derived from Reishi mushrooms and application thereof', and describes a cosmetic composition for skin whitening containing ganadomanandiol, an inhibitor of melanin biosynthesis and tyrosinase activity from the fruiting body of Reishi mushrooms, as an active ingredient.

[0006] However, the use of reishi mushroom mycelia culture for skin protection of companion animals has not yet been reported, and as reishi mushrooms are expensive raw materials, research and development of technologies including additional processes such as fermentation to further enhance their effectiveness is required.

[0007] Accordingly, the inventors of the present invention have completed the present invention by including an additional process to improve the function of the effective ingredients of triterpenoids such as ganadomanandiol contained in the mycelia of the reishi mushroom, and to utilize it for the purpose of improving the skin of companion animals.

[0008] Accordingly, the purpose of the present invention is to provide a composition for skin regeneration of a companion animal comprising a culture of Reishi mushroom mycelia or a lactic acid bacteria fermentation product of the culture.

[0009] Another object of the present invention is to provide a pharmaceutical composition for preventing or treating atopy or allergy in companion animals, comprising a culture of Reishi mushroom mycelia or a fermented product of the culture using lactic acid bacteria.

[0010] Another object of the present invention is to provide a pharmaceutical composition for preventing and treating inflammatory skin diseases in companion animals, comprising a culture of Reishi mushroom mycelia or a lactic acid bacteria fermentation product of the culture.

[0011] Another object of the present invention is to provide an antibacterial or antifungal composition for companion animals comprising a culture of Reishi mushroom mycelia or a lactic acid fermented product of the culture.

[0012] Another object of the present invention is to provide a composition for improving the coat quality of companion animals, comprising a culture of Reishi mushroom mycelia or a fermented product of the culture with lactic acid bacteria.

[0013] In order to achieve the above purpose, the present invention provides a composition for skin regeneration of a companion animal comprising a culture of Reishi mushroom mycelia or a fermented product of the culture with lactic acid bacteria.

[0014] In order to achieve another object of the present invention, the present invention provides a pharmaceutical composition for preventing or treating atopy or allergy in a companion animal, comprising a culture of Reishi mushroom mycelia or a fermented product of the culture using lactic acid bacteria.

[0015] In order to achieve another object of the present invention, the present invention provides a pharmaceutical composition for preventing and treating inflammatory skin diseases in companion animals, comprising a culture of Reishi mushroom mycelia or a fermented product of the culture using lactic acid bacteria.

[0016] In order to achieve another object of the present invention, the present invention provides an antibacterial or antifungal composition for companion animals comprising a culture of Reishi mushroom mycelia or a lactic acid bacteria fermentation product of the culture.

[0017] In order to achieve another object of the present invention, the present invention provides a composition for improving the coat of a companion animal, comprising a culture of Reishi mushroom mycelia or a fermented product of the culture with lactic acid bacteria.

[0018] Hereinafter, the present invention will be described in detail.

[0019] As one aspect of the present invention, the present invention relates to a composition comprising a culture of Reishi mushroom mycelia or a lactic acid bacteria fermentation product of the culture.

[0020] The reishi mushroom mycelia culture included in the composition of the present invention is a result of culturing reishi mushroom mycelia in various media, and may include reishi mushroom mycelia and a medium composition thereof. The medium included in the reishi mushroom mycelia culture is not limited in type, and may additionally include various medium compositions described in Korean Patent No. 10-2502920 or 10-1863229, which are prior documents of the present invention. As an example, the medium of the present invention may include molasses, corn steep liquor, salicylic acid, or lacquer tree extract, and may have the function of cultivating reishi mushroom mycelia and enhancing the content of effective ingredients such as ganadomanandiol included in reishi mushroom mycelia. In addition to the above substances, the medium of the present invention may include a typical medium composition for culturing mushroom mycelia.

[0021] The composition of the present invention may be a fermented product obtained by fermenting the above-described reishi mushroom mycelia culture with lactic acid bacteria. The lactic acid bacteria may be of marine origin and may be one or more strains selected from Pediococcus inopinatus, Lati lactobacillus sakei, Lactobacillus pentosus, Lactobacillus curvatus, or Weissella cibaria, and more preferably Lati lactobacillus sakei, Lactobacillus pentosus, or Lactobacillus curvatus. The strain may be of marine origin, but is not limited thereto.

[0022] In one embodiment of the present invention, it was confirmed that the mycelial culture of the reishi mushroom of the present invention had increased various effects for improving the skin condition of a companion animal through fermentation by the strain.

[0023] The composition comprising the Reishi mushroom mycelia culture of the present invention or the lactic acid bacteria fermentation product of the culture has a skin regeneration effect in companion animals. As used herein, the term "skin regeneration" may refer to any action that replenishes a portion of the skin that has been lost or damaged, or promotes the proliferation and migration of skin cells. The above-mentioned skin regeneration may be interpreted to include improvement of skin damage caused by skin diseases or improvement of skin wounds.

[0024] In addition, a composition comprising the reishi mushroom mycelia culture of the present invention or a lactic acid bacteria fermentation product of the culture has a preventive or therapeutic effect on inflammatory skin diseases such as atopy and allergies.

[0025] In the present invention, "inflammation" is an immune response caused by various reasons, and can be induced by medicines, skin diseases, contact with specific substances, etc., and can be caused by excessive production of reactive oxygen species (ROS) and reactive oxygen species (RNS). During the inflammatory process, a large amount of proinflammatory cytokines, nitric oxide (NO), and prostaglandin E2 (PGE2), inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2), etc. are generated. In addition, the inflammation can also be caused by diseases caused by excessive immune responses, such as atopy or allergy, and the composition of the present invention has an effect of preventing or treating various diseases occurring on the skin of companion animals or inflammation caused by excessive immunity, such as atopy or allergy, in particular.

[0026] In addition, the composition of the present invention may have an antibacterial or antifungal effect against various causative agents that cause skin diseases in companion animals. As used herein, the term "antibacterial" means an action that inhibits or controls the growth and proliferation of microorganisms such as bacteria or fungi, and in the present invention, it includes antibacterial and antifungal activity against one or more causative agents selected from the group consisting of Aspergillus Flavus, Aspergillus Niger, Candida albicans, Saccharomyces cerevisiae, M. restricta, T. mentagrophytes, P. acnes, dermatophytes, yeast, and Demodex that cause skin diseases in animals, such as itching and hair loss.

[0027] Additionally, the composition of the present invention has an effect of improving the hair quality of companion animals. The term "improving hair quality" refers to improving the hair condition of companion animals, such as by improving the shine of the hair, preventing matting, and preventing hair loss.

[0028] The composition of the present invention may be a pharmaceutical composition for companion animals. The pharmaceutical composition may further comprise a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable" as used herein means that the composition exhibits non-toxic properties to cells or humans exposed to the composition. The carrier may be any known in the art, such as a buffer, preservative, analgesic, solubilizer, isotonic agent, stabilizer, base, excipient, or lubricant, without limitation.

[0029] In addition, the pharmaceutical composition of the present invention can be formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., external preparations, suppositories, and sterile injection solutions, respectively, according to conventional methods. Furthermore, it can be used in the form of external preparations for skin in the form of ointments, lotions, sprays, patches, creams, powders, suspensions, gels, or gels. Carriers, excipients, and diluents that may be included in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil. When formulated, the composition is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.

[0030] Meanwhile, the pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. The term "administration" in the present invention refers to introducing a predetermined substance into an individual through an appropriate method, and the administration route of the composition may be administered through any common route as long as it can reach the target tissue. It may be intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, intranasal administration, intrapulmonary administration, or rectal administration, but is not limited thereto.

[0031] The above term "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment and not causing side effects, and the effective dosage level can be easily determined by those skilled in the art based on factors including the patient's sex, age, weight, health condition, type and severity of disease, activity of the drug, sensitivity to the drug, method of administration, time of administration, route of administration, and excretion rate, duration of treatment, drugs used in combination or simultaneously, and other factors well known in the medical field. Administration may be administered once a day at the above recommended dosage or may be administered in several divided doses.

[0032] In addition, the composition of the present invention may be feed or feed additive for companion animals. "Feed" refers to something that provides nutrition to livestock, companion animals, fish, etc. or is necessary for maintaining health or growth, and includes single feed, compound feed, etc. that are mixed with feed additives. The feed in the present invention may be feed for livestock or companion animals, and more preferably, feed for companion animals. In addition, "feed additive" refers to a feed additive that includes ingredients and substances that are added to compound feed to exhibit effects such as improving digestibility, reducing pathogens, improving fat metabolism, having an antioxidant effect, and removing toxic substances. Feed additives that can generally be added to animal feed include preservatives, amino acids, vitamins, probiotics, enzymes, etc.

[0033] In addition, the composition of the present invention may be a cosmetic composition. A cosmetic is an external skin preparation used for the purpose of improving the skin condition, and is not limited to the form thereof, and may be manufactured in all forms of formulations including, but not limited to, essence, solution, ointment, paste, cream, gel, foam, emulsifier, milk, soap, liquid cleanser, suspension, emulsion, lotion, powder, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, patch, and spray.

[0034] Additionally, the cosmetic composition may further include other ingredients typically incorporated into cosmetics, as needed. Examples thereof include, but are not limited to, a fat-containing ingredient, a moisturizer, an emollient, a surfactant, an organic pigment, an inorganic pigment, an organic powder, a preservative, a fragrance, a sterilizing agent, an antioxidant, an anti-oxidant, a pH adjuster, alcohol, a foaming agent, a filler, a colorant, a gelling agent, and purified water.

[0035] In the present invention, the cosmetic composition may additionally include a carrier acceptable as a cosmetic composition in the art. For example, one or more of oil, water, surfactants, moisturizers, lower alcohols, thickeners, chelating agents, pigments, preservatives, fragrances, etc. may be used, but these are exemplary and not limiting.

[0036] When the formulation of the cosmetic composition of the present invention is an ointment, paste, cream or gel, the carrier may be animal oil, vegetable oil, wax, paraffin, starch, cellulose derivative, polyethylene glycol, bentonite, silica, etc., but is not limited thereto, and the carrier may be used alone or in a mixture of two or more.

[0037] When the cosmetic composition of the present invention is a soap, foam, liquid detergent or surfactant-containing cleansing, the carrier may be an anionic surfactant, a nonionic surfactant, a fatty acid, an alkali metal salt of a fatty acid, an aliphatic alcohol, a vegetable oil, glycerol, glycerin, sugar, a lanolin derivative, or the like, but is not limited thereto, and the carrier may be used alone or in combination of two or more.

[0038] The present invention relates to a composition for skin regeneration, skin diseases such as atopy and allergies, skin inflammation, antibacterial or antifungal treatment, and hair quality improvement in companion animals, comprising a culture of Reishi mushroom mycelia or a fermented product of the culture with lactic acid bacteria, and has a preventive or improving effect on skin and hair diseases in companion animals.

[0039] Figure 1 shows the results of a DPPH activity inhibition experiment to confirm the antioxidant effect of the reishi mushroom mycelia culture of the present invention.

[0040] Figure 2 shows the results of an experiment to confirm the elastase inhibitory activity of the mycelial culture of the reishi mushroom of the present invention.

[0041] Figure 3 shows the results of an experiment to confirm the tyrosinase inhibitory activity of the mycelial culture of the reishi mushroom of the present invention.

[0042]

[0043] As one aspect of the present invention, the present invention relates to a composition for skin regeneration or hair quality improvement of a companion animal, comprising a culture of Reishi mushroom mycelia or a fermented product of the culture using lactic acid bacteria.

[0044] In another aspect of the present invention, the present invention relates to a pharmaceutical composition for preventing or treating atopy or allergy in a companion animal, comprising a culture of Reishi mushroom mycelia or a fermented product of the culture using lactic acid bacteria.

[0045] In another aspect of the present invention, the present invention relates to a pharmaceutical composition for preventing and treating inflammatory skin diseases in companion animals, comprising a culture of Reishi mushroom mycelia or a lactic acid bacteria fermentation product of the culture.

[0046] In another aspect of the present invention, the present invention relates to an antibacterial or antifungal composition for companion animals comprising a culture of Reishi mushroom mycelia or a lactic acid bacteria fermentation product of the culture.

[0047] As an example, the antibacterial or antifungal composition has an antibacterial or antifungal effect against one or more causative agents selected from the group consisting of Aspergillus Flavus, Aspergillus Niger, Candida albicans, Saccharomyces cerevisiae, M. restricta, T. mentagrophytes, P. acnes, dermatophytes, yeast, and Demodex.

[0048] As an example, the above reishi mushroom is characterized by being a reishi mushroom mycelium.

[0049] As an example, the lactic acid bacteria fermentation product is fermented by any one of the lactic acid bacteria Lati lactobacillus sakei, Lactobacillus pentosus, or Lactobacillus curvatus.

[0050] As an example, the composition is characterized in that it is a topical skin preparation.

[0051] As an example, the composition is characterized in that it is an oral composition.

[0052] As an example, the composition is characterized in that it is a cosmetic composition.

[0053] As an example, the composition is characterized in that it is a feed or feed additive composition.

[0054]

[0055] Hereinafter, examples will be described in detail to specifically explain this specification. However, the embodiments according to this specification may be modified in various different forms, and the scope of this specification is not limited to the embodiments described below. The embodiments of this specification are provided to more fully explain this specification to those of average skill in the art.

[0056]

[0057] Example 1. Preparation of Reishi mushroom mycelia culture and fermented product

[0058] 1-1) Production of Reishi mushroom mycelia

[0059] The mycelia of Reishi mushroom were isolated and cultured aseptically on PDA (containing 15 g of agar, 4 g of potato extract, and 20 g of glucose per 1 L of culture medium) medium from Reishi No. 2, which was provided by the Mushroom Division of the National Institute of Horticultural and Herbal Science, Rural Development Administration.

[0060] 1-2) Preparation of Reishi mushroom mycelia culture

[0061] To prepare a liquid culture medium for increasing the content of ganadomanandiol in the mycelia of Reishi mushroom, 100 ml of PDB medium (potato dextrose broth, containing 4 g of potato extract and 20 g of glucose per 1 L of culture medium) was added to a 250 ml Erlenmeyer flask to concentrations of 1, 5, 10, and 15% (v / v), respectively, and the Reishi mushroom mycelia of 1-1 were aseptically cut into 5 mm pieces, and 10 pieces of 100 mg of mycelia were placed in each 250 ml Erlenmeyer flask, followed by shaking culture at 28°C and 100 rpm for 5 days.

[0062] 1-3) Production of fermented reishi mushroom mycelia

[0063] Latilactobacillus sakei subsp. Sakei (M21F010) was added to the above reishi mushroom mycelia culture and further cultured.

[0064] The strain was confirmed to be capable of growth under conditions of temperature between 20°C and 35°C, salinity between 0% and 7%, and pH 4 to pH 10, and in this experimental example, it was cultured under conditions of 30°C, 1% salinity, and pH 5.

[0065] 1-4) Preparation of Reishi mushroom mycelia extract

[0066] The above-mentioned cultured Ganoderma lucidum mycelia were separated from the culture medium and dried at 60°C for 3 days. 50 ml of 70% ethanol was added to 0.2 g of the dried sample, and the mixture was refluxed and extracted twice at 85°C for 2 hours. Only the extract was filtered using a filter paper. The obtained extract was concentrated under reduced pressure to obtain 50 mg of Ganoderma lucidum mycelia extract.

[0067] Example 2. Confirmation of the content of effective ingredients in fermented reishi mushroom mycelia.

[0068] The content of ganadomananediol, an active ingredient contained in the fermented mycelia of the reishi mushroom manufactured above, was compared with that of the reishi mushroom mycelia and strain culture medium. The quantification of ganadomananediol was performed using HPLC (SPD-20A UV / VIS Deteor, LC-20AT Pumping System, Manual Injection Value 20ul Loop, Shimadzu Corp., Japan) equipped with a Phenomenex Luna C18UV(2) column (4.6 x 250 mm, 5 um, USA). The mobile phase was acetonitrile and 0.2% acetic acid, and the flow rate was 0.8 ml / min, and the measurement was performed at 245 nm with a UV (ultraviolet-visible) detector. In addition, ChemFace ®(China) was used as a standard material to perform quantitative analysis of ganadomananediol in Ganoderma lucidum mycelia. The ganadomananediol content in Ganoderma lucidum mycelia was analyzed according to the concentration of lacquer tree extract added to the Ganoderma lucidum culture medium, and the results are shown in Table 1 below.

[0069] Experimental group Ganadomannane diol content (mg) Reishi mushroom mycelia + Latilactobacillus sakei subsp. Sakei (M21F010) strain 3.45 ± 0.17 Reishi mushroom mycelia (Comparative Example 1) 1.63 ± 0.08 Latilactobacillus sakei subsp. Sakei (M21F010) strain culture medium (Comparative Example 2) 0

[0070] As shown in the table above, it was confirmed that the content of ganadomanandiol increased in the fermented product of Reishi mushroom mycelia compared to the mycelia or strain culture solution.

[0071]

[0072] Experimental Example 1. Confirmation of the antioxidant (anti-inflammatory) effect of fermented Reishi mushroom mycelia.

[0073] To confirm the antioxidant effect of the fermented Ganoderma lucidum mycelia, a DPPH inhibitory activity test was conducted. To compare the activity, 1,1-diphenyl-2-picrylhydrazyl (DPPH) solution was added to the Ganoderma lucidum mycelia (Comparative Example 1), the Latilactobacillus sakei culture medium containing no Ganoderma lucidum mycelia (Comparative Example 2), and the fermented Ganoderma lucidum mycelia of the present invention, stirred, allowed to stand for 10 minutes or more, and the absorbance was measured.

[0074] As a result, as shown in Fig. 1, in the case of fermented Reishi mushroom mycelia, the DPPH inhibitory activity was higher than in other experimental groups, and it was confirmed that this increased in a concentration-dependent manner.

[0075] Experimental Example 2. Confirmation of the skin regeneration effect of fermented reishi mushroom mycelia.

[0076] 2-1) Measurement of elastase inhibitory activity of Reishi mushroom mycelia culture

[0077] To confirm the skin regeneration and hair quality improvement effects of fermented Reishi mushroom mycelia, the inhibitory activity of elastase, an enzyme that promotes the decomposition of elastin, a protein that is a component of skin and hair, was measured. To compare the activity, Reishi mushroom mycelia (Comparative Example 1) and Latilactobacillus sakei cultures containing no Reishi mushroom mycelia (Comparative Example 2) were treated with elastase using the same method, and the results were compared.

[0078] As a result, as shown in Fig. 2, the elastase inhibitory activity of the fermented Reishi mushroom mycelia was higher than that of the other experimental groups. From this, it can be confirmed that the fermented Reishi mushroom mycelia has a concentration-dependent skin regeneration and hair quality improvement effect.

[0079] 2-2) Measurement of tyrosinase inhibitory activity of reishi mushroom mycelia culture

[0080] To confirm the skin damage recovery effect of fermented Reishi mushroom mycelia, the inhibitory activity of tyrosinase was measured. The DOPA chrome produced as a result of the action of tyrosinase was measured by colorimetry to confirm the change in activity. To compare the activity with each experimental group, Reishi mushroom mycelia (Comparative Example 1) and Latilactobacillus sakei culture solution without Reishi mushroom mycelia (Comparative Example 2) were treated to skin cells using the same method, and the results were compared.

[0081] As a result, as shown in Figure 3, the fermented Reishi mushroom mycelia exhibited higher tyrosinase inhibitory activity than the other experimental groups. From this, it was confirmed that the fermented Reishi mushroom mycelia exhibited a concentration-dependent recovery effect on skin damage.

[0082] Experimental Example 2. Confirmation of the antibacterial effect of fermented Reishi mushroom mycelia.

[0083] In order to confirm the antibacterial effect of the fermented Reishi mushroom mycelia, the antibacterial activity against four types of fungi (Aspergillus flavus, Aspergillus niger, Candida albicans, and Saccharomyces cerevisiae) that mainly cause skin diseases on the skin of companion animals was measured. In order to compare the activity of the fermented Reishi mushroom mycelia with the above four types of fungi, the Reishi mushroom mycelia and the Latilactobacillus sakei culture medium without the Reishi mushroom mycelia were treated in the same manner as above, and the results were compared as shown in Table 2 below.

[0084] Aspergillus FlavusAspergillus nigerCandida albicansSaccharomyces cerevisiaeExperimental group++++++++Reishi mushroom mycelia + Latilactobacillus sakei subsp. Sakei (M21F010) strain+++++Reishi mushroom mycelia (Comparative example 1)+++++

[0085] The present invention has been described above, focusing on preferred embodiments thereof. Those skilled in the art will appreciate that the present invention can be implemented in modified forms without departing from its essential characteristics. Therefore, the disclosed embodiments should be considered illustrative rather than restrictive. The scope of the present invention is set forth in the claims, not the foregoing description, and all differences within the scope equivalent thereto should be construed as being encompassed by the present invention.

Claims

1. A composition for skin regeneration or hair quality improvement of a companion animal, comprising a culture of reishi mushroom mycelia or a fermented product of the culture using lactic acid bacteria.

2. A pharmaceutical composition for preventing or treating atopy or allergy in a companion animal, comprising a culture of reishi mushroom mycelia or a fermented product of the culture using lactic acid bacteria.

3. A pharmaceutical composition for preventing and treating inflammatory skin diseases in companion animals, comprising a culture of reishi mushroom mycelia or a fermented product of the culture using lactic acid bacteria.

4. An antibacterial or antifungal composition for companion animals comprising a culture of Reishi mushroom mycelia or a lactic acid bacteria fermentation product of the culture.

5. In paragraph 4, The above antibacterial or antifungal composition is a composition having an antibacterial or antifungal effect against one or more causative agents selected from the group consisting of Aspergillus Flavus, Aspergillus Niger, Candida albicans, Saccharomyces cerevisiae, M. restricta, T. mentagrophytes, P. acnes, dermatophytes, yeast, and Demodex.

6. In any one of paragraphs 1 to 4, A composition characterized in that the above reishi mushroom is reishi mushroom mycelia.

7. In any one of paragraphs 1 to 4, The above lactic acid bacteria fermentation product is a composition fermented by any one of lactic acid bacteria of Lati lactobacillus sakei, Lactobacillus pentosus, or Lactobacillus curvatus.

8. In any one of paragraphs 1 to 4, A composition characterized in that the above composition is a skin external application agent.

9. In any one of paragraphs 1 to 4, A composition characterized in that the above composition is an oral composition.

10. In paragraph 1 or paragraph 4, A composition characterized in that the above composition is a cosmetic composition.

11. In paragraph 1 or paragraph 4, A composition characterized in that the composition is a feed or feed additive composition.

Images